During the past decade, California Neuroscience Research Medical Group, Inc conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 30 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 19 clinical trials were completed. i.e. 111.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "California Neuroscience Research Medical Group, Inc" #1 sponsor was "Pfizer" with 9 trials, followed by "Naurex, Inc, an affiliate of Allergan plc" with 6 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Biogen" with 4 trials sponsored and "Biohaven Pharmaceuticals, Inc." with 4 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "California Neuroscience Research Medical Group, Inc" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Banner Alzheimer's Institute" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Institute for the Study of Aging (ISOA)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "California Neuroscience Research Medical Group, Inc" are "Alzheimer's Disease" (14 trials), "Alzheimer Disease" (8 trials), "Depressive Disorder, Major" (8 trials), "Major Depressive Disorder" (6 trials) and "Depression" (3 trials). Many other conditions were trialed in "California Neuroscience Research Medical Group, Inc" in a lesser frequency.

Most popular intervention types in "California Neuroscience Research Medical Group, Inc" are "Drug" (55 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Rapastinel" (6 trials), "Gantenerumab" (5 trials), "Aducanumab" (4 trials) and "ADT" (3 trials). Other intervention names were less common.

The vast majority of trials in "California Neuroscience Research Medical Group, Inc" are 55 trials for "All" genders.

Currently, there are NaN active trials in "California Neuroscience Research Medical Group, Inc". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 27 completed trials in California Neuroscience Research Medical Group, Inc, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in California Neuroscience Research Medical Group, Inc, 0 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".